Invivyd Inc (IVVD)

$0.58 +0.04 (7.11%)
Market Cap 174.79M
Revenue (ttm) 53.43M
Net Income (ttm) -52.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -98.24%
Debt to Equity Ratio 0.00
Volume 3,057,300
Avg Vol 4,723,870
Day's Range N/A - N/A
Shares Out 294.61M
Stochastic %K 4%
Beta 0.67
Analysts Strong Sell
Price Target $10.00

Company Profile

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 819 0080
Address:
209 Church Street, New Haven, United States
SHVR89
SHVR89 Jul. 30 at 4:04 PM
$IVVD trading at $0.57 while hiring a full national sales team RIGHT NOW LinkedIn past 48hrs: Regional Sales Directors, Virology Specialists, Thought Leader Liaisons, Reimbursement Managers — coast to coast. Salaries $120K-$245K. You don't build a launch team if you don't have something to launch
2 · Reply
billsmall
billsmall Jul. 29 at 7:55 PM
$IVVD Damn, way to early. Looks like new lows coming soon.
0 · Reply
Jack696
Jack696 Jul. 29 at 5:05 PM
$IVVD not looking good for this company. Not going to lie
0 · Reply
aigoat777
aigoat777 Jul. 29 at 4:40 PM
$IVVD Company burns so much money per Quarter. If there is no news, they may do RS.
1 · Reply
student56
student56 Jul. 29 at 4:06 PM
$IVVD buy more and hold
0 · Reply
alexx013
alexx013 Jul. 29 at 3:47 PM
$IVVD added @ .567
0 · Reply
gb2017384
gb2017384 Jul. 29 at 3:26 PM
$IVVD THE BOTTOM IS ALMOST HERE$.
0 · Reply
daybaron
daybaron Jul. 29 at 2:30 PM
$IVVD 57 fucking cents..... on way to $10 by way of $.10
1 · Reply
student56
student56 Jul. 29 at 1:38 PM
$IVVD adding here
0 · Reply
Rynr
Rynr Jul. 29 at 5:56 AM
$IVVD This feels like a psychological battle and the ultimate test of patience. I believe those who remain patient will be rewarded handsomely.
0 · Reply
Latest News on IVVD
Invivyd announces notice of termination for Pemgarda Emergency Use Authorization

2026-07-06T11:20:28.000Z - 24 days ago

Invivyd announces notice of termination for Pemgarda Emergency Use Authorization

Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

Jul 6, 2026, 7:01 AM EDT - 24 days ago

Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 2, 2026, 7:01 AM EDT - 4 weeks ago

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Jun 29, 2026, 7:00 AM EDT - 4 weeks ago

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

NBP

Invivyd completes enrollment of LIBERTY clinical trial

2026-06-16T11:37:10.000Z - 6 weeks ago

Invivyd completes enrollment of LIBERTY clinical trial

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Jun 16, 2026, 7:01 AM EDT - 6 weeks ago

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration

Jun 9, 2026, 7:01 AM EDT - 7 weeks ago

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration

Invivyd Transcript: H.C. Wainwright “HCW @ Home” Series

Jun 8, 2026, 10:00 AM EDT - 7 weeks ago

Invivyd Transcript: H.C. Wainwright “HCW @ Home” Series

Invivyd Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 4:55 PM EDT - 2 months ago

Invivyd Transcript: Jefferies Global Healthcare Conference 2026

Invivyd completes enrollment in DECLARATION trial

2026-06-01T11:06:59.000Z - 2 months ago

Invivyd completes enrollment in DECLARATION trial

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Jun 1, 2026, 7:01 AM EDT - 2 months ago

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Invivyd to Participate in Upcoming Investor Events

May 27, 2026, 7:01 AM EDT - 2 months ago

Invivyd to Participate in Upcoming Investor Events

Invivyd management to meet with BTIG

2026-05-19T19:50:10.000Z - 2 months ago

Invivyd management to meet with BTIG

Invivyd Transcript: AGM 2026

May 19, 2026, 8:30 AM EDT - 2 months ago

Invivyd Transcript: AGM 2026

Invivyd post earnings selloff overdone, says H.C. Wainwright

2026-05-14T19:05:42.000Z - 2 months ago

Invivyd post earnings selloff overdone, says H.C. Wainwright

Invivyd Earnings Call Transcript: Q1 2026

May 14, 2026, 8:30 AM EDT - 2 months ago

Invivyd Earnings Call Transcript: Q1 2026

Invivyd Earnings release: Q1 2026

May 14, 2026, 8:30 AM EDT - 2 months ago

Invivyd Earnings release: Q1 2026

Invivyd Slides: Q1 2026

May 14, 2026, 8:30 AM EDT - 2 months ago

Invivyd Slides: Q1 2026

Invivyd Quarterly report: Q1 2026

May 14, 2026, 8:30 AM EDT - 2 months ago

Invivyd Quarterly report: Q1 2026

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 14, 2026, 7:01 AM EDT - 2 months ago

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

May 11, 2026, 7:01 AM EDT - 2 months ago

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

May 7, 2026, 7:01 AM EDT - 3 months ago

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

Invivyd annouces Chairman Elia to speak at POLITICO Health Care Summit

2026-04-20T11:28:23.000Z - 3 months ago

Invivyd annouces Chairman Elia to speak at POLITICO Health Care Summit

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Apr 20, 2026, 7:01 AM EDT - 3 months ago

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd provides update on Phase 3 DECLARATION study of VYD2311

2026-04-09T13:34:05.000Z - 4 months ago

Invivyd provides update on Phase 3 DECLARATION study of VYD2311

Invivyd announces discovery, advancement of measles antibody candidate VMS063

2026-04-09T13:33:36.000Z - 4 months ago

Invivyd announces discovery, advancement of measles antibody candidate VMS063

Invivyd Transcript: Study update

Apr 9, 2026, 8:30 AM EDT - 4 months ago

Invivyd Transcript: Study update

Invivyd Press release: Study update

Apr 9, 2026, 8:30 AM EDT - 4 months ago

Invivyd Press release: Study update

Invivyd Slides: Study update

Apr 9, 2026, 8:30 AM EDT - 4 months ago

Invivyd Slides: Study update

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Apr 9, 2026, 7:01 AM EDT - 4 months ago

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Invivyd Proxy statement: Proxy filing

Invivyd Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Invivyd Proxy statement: Proxy filing

Invivyd Announces Presentation at the World Vaccine Congress Washington

Mar 30, 2026, 4:05 PM EDT - 4 months ago

Invivyd Announces Presentation at the World Vaccine Congress Washington

Invivyd Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 5 months ago

Invivyd Earnings Call Transcript: Q4 2025

Invivyd Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 5 months ago

Invivyd Annual report: Q4 2025

Invivyd Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 5 months ago

Invivyd Earnings release: Q4 2025

Invivyd Slides: Q4 2025

Mar 5, 2026, 8:30 AM EST - 5 months ago

Invivyd Slides: Q4 2025

Invivyd reports cash, cash equivalents of $226.7M as of December 31

2026-03-05T12:20:54.000Z - 5 months ago

Invivyd reports cash, cash equivalents of $226.7M as of December 31

Invivyd appoints Michael Mina as CMO

2026-03-05T12:20:37.000Z - 5 months ago

Invivyd appoints Michael Mina as CMO

Invivyd reports FY25 EPS (30c) vs. ($1.43) last year

2026-03-05T12:13:36.000Z - 5 months ago

Invivyd reports FY25 EPS (30c) vs. ($1.43) last year

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Mar 5, 2026, 7:03 AM EST - 5 months ago

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Mar 5, 2026, 7:01 AM EST - 5 months ago

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Mar 2, 2026, 4:10 PM EST - 5 months ago

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Invivyd announces peer-reviewed publication using CANOPY trial data

2026-02-24T12:48:12.000Z - 5 months ago

Invivyd announces peer-reviewed publication using CANOPY trial data

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Feb 24, 2026, 7:01 AM EST - 5 months ago

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Invivyd management to meet virtually with BTIG

2026-02-18T17:40:26.000Z - 5 months ago

Invivyd management to meet virtually with BTIG

Invivyd aligns with FDA on LIBERTY Phase 3 trial of VYD2311

2026-02-03T12:05:43.000Z - 6 months ago

Invivyd aligns with FDA on LIBERTY Phase 3 trial of VYD2311

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

Feb 3, 2026, 7:01 AM EST - 6 months ago

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

Invivyd announces partnership with ski champion Lindsey Vonn

2026-01-22T12:16:53.000Z - 6 months ago

Invivyd announces partnership with ski champion Lindsey Vonn

Invivyd, SPEAR Study Group plan to initiate Phase 2 trial of VYD2311

2026-01-20T12:11:41.000Z - 6 months ago

Invivyd, SPEAR Study Group plan to initiate Phase 2 trial of VYD2311

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Jan 20, 2026, 7:01 AM EST - 6 months ago

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Jan 8, 2026, 7:01 AM EST - 7 months ago

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Invivyd Slides: Corporate Presentation

Jan 8, 2026, 7:00 AM EST - 7 months ago

Invivyd Slides: Corporate Presentation

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:05 AM EST - 7 months ago

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:01 AM EST - 7 months ago

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Registration statement: Registration Filing

Dec 19, 2025, 7:00 AM EST - 7 months ago

Invivyd Registration statement: Registration Filing

Invivyd Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 2:35 PM EST - 8 months ago

Invivyd Transcript: Evercore ISI 8th Annual HealthCONx Conference

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:01 AM EST - 8 months ago

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Nov 24, 2025, 7:01 AM EST - 8 months ago

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 17, 2025, 10:40 PM EST - 9 months ago

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Proposed Public Offering of Common Stock

Nov 17, 2025, 4:01 PM EST - 9 months ago

Invivyd Announces Proposed Public Offering of Common Stock

Invivyd Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Invivyd Earnings Call Transcript: Q3 2025

Invivyd Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Invivyd Quarterly report: Q3 2025

Invivyd Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Invivyd Earnings release: Q3 2025

Invivyd Slides: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Invivyd Slides: Q3 2025

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:01 AM EST - 9 months ago

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Nov 3, 2025, 4:01 PM EST - 9 months ago

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Invivyd Transcript: Study Update

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Invivyd Transcript: Study Update

Invivyd Press release: Study Update

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Invivyd Press release: Study Update

Invivyd Slides: Study Update

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Invivyd Slides: Study Update

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 28, 2025, 7:01 AM EDT - 9 months ago

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 6, 2025, 7:01 AM EDT - 10 months ago

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Registration statement: Registration Filing

Oct 2, 2025, 8:00 AM EDT - 10 months ago

Invivyd Registration statement: Registration Filing

Invivyd Appoints Paul B. Bolno, M.D.

Sep 24, 2025, 4:01 PM EDT - 11 months ago

Invivyd Appoints Paul B. Bolno, M.D.

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Sep 17, 2025, 7:01 AM EDT - 11 months ago

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Invivyd Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 12:00 PM EDT - 11 months ago

Invivyd Transcript: H.C. Wainwright 27th Annual Global Investment Conference

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Sep 4, 2025, 7:01 AM EDT - 11 months ago

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Invivyd Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 2:10 PM EDT - 11 months ago

Invivyd Transcript: Cantor Global Healthcare Conference 2025

Invivyd to Participate in Upcoming Investor Conferences

Aug 27, 2025, 7:01 AM EDT - 1 year ago

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Aug 22, 2025, 12:00 PM EDT - 1 year ago

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Aug 20, 2025, 11:58 PM EDT - 1 year ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Aug 18, 2025, 4:32 PM EDT - 1 year ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:49 PM EDT - 1 year ago

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Aug 14, 2025, 4:47 PM EDT - 1 year ago

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Invivyd Quarterly report: Q2 2025

Aug 14, 2025, 9:30 AM EDT - 1 year ago

Invivyd Quarterly report: Q2 2025

Invivyd Earnings release: Q2 2025

Aug 14, 2025, 9:30 AM EDT - 1 year ago

Invivyd Earnings release: Q2 2025

Invivyd Slides: Q2 2025

Aug 14, 2025, 9:30 AM EDT - 1 year ago

Invivyd Slides: Q2 2025

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 23, 2025, 7:01 AM EDT - 1 year ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Jul 21, 2025, 7:05 AM EDT - 1 year ago

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 2, 2025, 7:01 AM EDT - 1 year ago

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Jun 26, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 27, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 23, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 21, 2025, 9:30 AM EDT - 1 year ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 11:00 AM EDT - 1 year ago

Invivyd Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Invivyd Earnings Call Transcript: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Earnings Call Transcript: Q1 2025

Invivyd Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Quarterly report: Q1 2025

Invivyd Earnings release: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Earnings release: Q1 2025

Invivyd Slides: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Slides: Q1 2025

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 7:01 AM EDT - 1 year ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 14, 2025, 7:01 AM EDT - 1 year ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 7:01 AM EDT - 1 year ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

May 12, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

SHVR89
SHVR89 Jul. 30 at 4:04 PM
$IVVD trading at $0.57 while hiring a full national sales team RIGHT NOW LinkedIn past 48hrs: Regional Sales Directors, Virology Specialists, Thought Leader Liaisons, Reimbursement Managers — coast to coast. Salaries $120K-$245K. You don't build a launch team if you don't have something to launch
2 · Reply
billsmall
billsmall Jul. 29 at 7:55 PM
$IVVD Damn, way to early. Looks like new lows coming soon.
0 · Reply
Jack696
Jack696 Jul. 29 at 5:05 PM
$IVVD not looking good for this company. Not going to lie
0 · Reply
aigoat777
aigoat777 Jul. 29 at 4:40 PM
$IVVD Company burns so much money per Quarter. If there is no news, they may do RS.
1 · Reply
student56
student56 Jul. 29 at 4:06 PM
$IVVD buy more and hold
0 · Reply
alexx013
alexx013 Jul. 29 at 3:47 PM
$IVVD added @ .567
0 · Reply
gb2017384
gb2017384 Jul. 29 at 3:26 PM
$IVVD THE BOTTOM IS ALMOST HERE$.
0 · Reply
daybaron
daybaron Jul. 29 at 2:30 PM
$IVVD 57 fucking cents..... on way to $10 by way of $.10
1 · Reply
student56
student56 Jul. 29 at 1:38 PM
$IVVD adding here
0 · Reply
Rynr
Rynr Jul. 29 at 5:56 AM
$IVVD This feels like a psychological battle and the ultimate test of patience. I believe those who remain patient will be rewarded handsomely.
0 · Reply
Chester_Copperpot85
Chester_Copperpot85 Jul. 28 at 9:59 PM
$IVVD Sitting at oversold on the 2 year RSI VERY BULLISH
0 · Reply
Chester_Copperpot85
Chester_Copperpot85 Jul. 28 at 9:48 PM
$IVVD https://archive.fast-edgar.com/20260728/AS2ZK22MF222N9Z222252ZO5JOUJZ222ME82/ good enough for Blackrock, good enough for me
1 · Reply
Penny_stock_Raid_Boss
Penny_stock_Raid_Boss Jul. 28 at 6:29 PM
$IVVD hey, so far so good tho. Just buy the dip.
1 · Reply
student56
student56 Jul. 28 at 2:40 PM
$IVVD OMG
0 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Jul. 26 at 11:50 PM
$IVVD Tuesday could be the bottom.
3 · Reply
DannyGh8st
DannyGh8st Jul. 26 at 8:05 PM
$IVVD Potential upside from clinical progress and regulatory milestoness!!!
1 · Reply
TWITLIEDETECTOR
TWITLIEDETECTOR Jul. 25 at 5:55 AM
$IVVD waiting for .48. they will pump it back
1 · Reply
billsmall
billsmall Jul. 23 at 6:00 PM
$IVVD At some point you're going to have to decide to avg down or close your eyes and hope for the best. I see a couple adding anybody here unloading or waiting until last minute. Also curious, anybody just swing this for pennies at a time? I will say it would be nice to get some type of communication on how if at all sales might be growing but I think silence kind of already tells us that.
2 · Reply
student56
student56 Jul. 23 at 2:57 PM
$IVVD looking good
1 · Reply
OlBob711
OlBob711 Jul. 23 at 2:49 PM
$IVVD as long as Steve Cohen is still holding over 7.5 M shares I’ll stay.
2 · Reply
gb2017384
gb2017384 Jul. 23 at 2:00 PM
$IVVD THIS LOOKS TO HEADED TO 50CENTS BEFORE IT BOTTOMS OUT,AND MAYBE D LISTED BY THE NASA.
0 · Reply
billsmall
billsmall Jul. 23 at 12:25 PM
$IVVD OK, nobody sells 100 shrs or less pre market of a $.63 stock unless they're trying to drive a direction. Total BS as is the whole financial markets in the US these days. Man have things changed over the past several yrs. 🤷‍♂️
0 · Reply